FDA Approval Summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer (Q38656596)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | FDA Approval Summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer |
scientific article |
Statements
1 reference
FDA Approval Summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer (English)
1 reference
Sanjeeve Balasubramaniam
1 reference
Julia A Beaver
1 reference
Sara Horton
1 reference
Laura L Fernandes
1 reference
Shenghui Tang
1 reference
Hisani N Horne
1 reference
Jinzhong Liu
1 reference
Chao Liu
1 reference
Sarah J Schrieber
1 reference
Jingyu Yu
1 reference
Pengfei Song
1 reference
William Pierce
1 reference
Kim J Robertson
1 reference
Todd R Palmby
1 reference
Haw-Jyh Chiu
1 reference
Eunice Y Lee
1 reference
Reena Philip
1 reference
Robert Schuck
1 reference
Rosane Charlab
1 reference
Anamitro Banerjee
1 reference
Xiao Hong Chen
1 reference
Xing Wang
1 reference
Kirsten B Goldberg
1 reference
Rajeshwari Sridhara
1 reference
Geoffrey Kim
1 reference
Richard Pazdur
1 reference
27 July 2017
1 reference
1 reference
Identifiers
1 reference